It is a weight-loss medication in the form of a pen injector, containing the active ingredient Liraglutide
NICE guidance (NG28) specifies that these agents should generally be considered in people with a BMI 30 kg/m (or lower in certain ethnic groups) and specific problems associated with high weight, or if insulin would have significant occupational implications
Eligibility criteria are strict, and participation involves thorough medical screening and ongoing monitoring
In cellular models, the product significantly enhanced GLP-1 secretion by up to 3.27 times compared to untreated groups
These drugs, widely used for weight loss, mimic a natural hormone in the body to help regulate appetite, slow digestion, and, for some people especially those living with type 2 diabetes lower blood glucose levels
The second approved indication is for chronic weight management in adults with obesity (BMI 30 kg/m) or those who are overweight (BMI 27 kg/m) with at least one weight-related comorbidity, such as hypertension, dyslipidaemia, or obstructive sleep apnoea
